MedTrace Logo

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

NCT02518113 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-09-11

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).

Conditions

  • T-cell Acute Lymphoblastic Leukemia
  • T-cell Lymphoblastic Lymphoma

Interventions

DRUG

LY3039478

Administered orally

DRUG

Dexamethasone

Administered orally

DRUG

Placebo

Administered orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2018-01-15
Completion
2018-01-15

Countries

  • United States
  • France
  • Germany
  • Israel
  • Italy

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02518113 on ClinicalTrials.gov